Clot, Clot, Who's There?

Inside the Lab: Bypassing Factor Xa Inhibitors

In urgent, high-stakes situations—like major bleeding or emergency surgery—how should clinicians assess coagulation in patients on factor Xa inhibitors? And more importantly, are we focusing on the right signal? Join global experts as they explore: * Why traditional assays (PT/aPTT, anti-Xa) often fall short in critical decision-making * The role of functional testing in assessing true hemostatic potential * How VMX-C001, a novel bypassing agent, challenges conventional approaches to reversal and monitoring Be sure to read the VMX-C001 study discussed in the episode: https://www.rpthjournal.org/article/S2475-0379(26)00033-6/fulltext?dgcid=raven_jbs_etoc_email [https://www.rpthjournal.org/article/S2475-0379(26)00033-6/fulltext?dgcid=raven_jbs_etoc_email] Tune in now and subscribe to Clot, Clot, Who's There? for more expert conversations bridging science, practice, and global perspectives in thrombosis, hemostasis, and vascular medicine. Chapters 00:00 Introduction & Clinical Challenge 02:54 Assessing Factor Xa Inhibitors in Urgent/Emergent Situations 05:29 Why Standard Assays Fall Short 09:38 Functional Testing: dPT & dRVVT 12:35 VMX-C001 & Future Directions This episode was made possible through generous support from VarmX.

Stopping the Second Stroke: Emerging Strategies in Secondary Prevention

Surviving a stroke is only the beginning. Preventing the next one is where the real clinical challenge lies—and for patients with non-cardioembolic stroke, the existing toolkit has long fallen short. Join Drs. Geoff Barnes, Mike Sharma, and Valeria Caso as they explore: * Stroke subtypes, recurrence risk, and the unique challenges of non-cardioembolic stroke and ESUS * Why current treatment options have fallen short—and what may be next * The advent of Factor XI inhibitors and what emerging data may mean for the future of secondary prevention Tune in now and subscribe to Clot, Clot, Who's There? for more expert conversations bridging science, practice, and global perspectives in thrombosis, hemostasis, and vascular medicine. * 00:00: Introduction & Stroke Subtypes * 03:59: Recurrence Risk & Key Risk Factors * 07:24: Current Treatment Strategies * 10:54: ESUS & Limits of Anticoagulation * 14:19: Moving Beyond Aspirin * 16:26: Factor XI Inhibitors: Data & Future Directions This episode was made possible through generous support from Bayer.

Precision Over Prescription: Antithrombotic Therapy and CAD

When it comes to antithrombotic therapy in coronary artery disease, the central question is no longer "What should everyone get?" It's "What's right for this patient?" In this episode, Drs. Heather Johnson, Ty Gluckman, and Davide Cappodano explore the modern balance between managing clotting and bleeding risk in patients on antiplatelets and anticoagulants. From the evolving role of aspirin and P2Y12 monotherapy to dual pathway inhibition and the management of CAD with atrial fibrillation, the conversation highlights a clear shift: less one-size-fits-all medicine, more individualized—and shared—decision-making. Tune in now and subscribe to Clot, Clot, Who's There? for more expert conversations bridging science, practice, and global perspectives in thrombosis, hemostasis, and vascular medicine. 00:00 – Welcome & Introduction 03:57 – Is Aspirin Still King? 10:26 – Shorter DAPT, Earlier Monotherapy 14:09 – When More Is More: the COMPASS regimen 17:49 – When Less Is More: CAD + AF

AF Gone, Clot Still Knocking?

In this episode of Clot, Clot, Who's There? Drs. Christian Ruff (USA) and Giulio Francesco Romiti (Italy) chat about long-term anticoagulation management after successful atrial fibrillation ablation. They explore why stroke risk may persist despite rhythm control, examine emerging evidence from the ALONE-AF and OCEAN trials, and consider how patient selection and shared decision-making should inform post-ablation care. Tune in now and subscribe to Clot, Clot, Who's There? for more expert conversations bridging science, practice, and global perspectives in thrombosis, hemostasis, and vascular medicine. 00:00 Welcome & Introductions 01:12 Why Stroke Risk Persists After AF Ablation 04:19 The Anticoagulation Dilemma: Guidelines, Risk & Patient Priorities 09:45 New Evidence After Ablation: ALONE-AF & OCEAN 27:12 Key Takeaways, Shared Decision-Making & What's Next

What's Clotting in 2026?

In this episode of Clot Clot Who's There, Aviva Schwartz, Director of Education at Vasculearn Network, speaks with Professor Gregory Lip about key anticoagulation and atrial fibrillation data from 2025 and what lies ahead in 2026. The discussion spans post–AF ablation management, holistic AF care, and emerging factor XI inhibitors shaping the future of thrombosis management. Tune in now and subscribe to Clot, Clot, Who's There? for more expert conversations bridging science, practice, and global perspectives in thrombosis, hemostasis, and vascular medicine. Chapters: 00:00 Welcome and Introduction 01:59 2025 Trial Highlights: Anticoagulation in Stable CAD and AF Ablation 07:27 High-Risk AF and Holistic Care 10:10 What's Coming in 2026: Factor XI Inhibitors and Upcoming Trials 11:51 Guidelines vs. Real-World Practice